MOLECULAR TEMPLATES INC (MTEM) Stock Price, Forecast & Analysis
USA - NASDAQ:MTEM - US6085502085 - Common Stock
MTEM Key Statistics, Chart & Performance
The current stock price of MTEM is 0.1072 USD. In the past month the price decreased by -73.31%. In the past year, price decreased by -97.13%.
MTEM Latest News, Press Relases and Analysis
MTEM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About MTEM
Company Profile
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 62 full-time employees. The company went IPO on 2005-02-04. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Company Info
MOLECULAR TEMPLATES INC
9301 Amberglen Blvd, Suite 100
Austin TEXAS 78729 US
CEO: Eric E. Poma
Employees: 62
Phone: 15128961555
MOLECULAR TEMPLATES INC / MTEM FAQ
What does MOLECULAR TEMPLATES INC do?
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 62 full-time employees. The company went IPO on 2005-02-04. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Can you provide the latest stock price for MOLECULAR TEMPLATES INC?
The current stock price of MTEM is 0.1072 USD. The price decreased by -23.43% in the last trading session.
What is the dividend status of MOLECULAR TEMPLATES INC?
MTEM does not pay a dividend.
How is the ChartMill rating for MOLECULAR TEMPLATES INC?
MTEM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting MTEM stock to perform?
7 analysts have analysed MTEM and the average price target is 18.36 USD. This implies a price increase of 17026.87% is expected in the next year compared to the current price of 0.1072.
Can you provide the market cap for MOLECULAR TEMPLATES INC?
MOLECULAR TEMPLATES INC (MTEM) has a market capitalization of 705.38K USD. This makes MTEM a Nano Cap stock.
MTEM Technical Analysis
MTEM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTEM. MTEM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MTEM Financial Highlights
Over the last trailing twelve months MTEM reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS increased by 78.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.52% | ||
| ROE | -219.7% | ||
| Debt/Equity | 0 |
MTEM Forecast & Estimates
7 analysts have analysed MTEM and the average price target is 18.36 USD. This implies a price increase of 17026.87% is expected in the next year compared to the current price of 0.1072.
For the next year, analysts expect an EPS growth of -92.81% and a revenue growth -78.76% for MTEM